Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution
| Autor: | Philippe Zrounba, Séverine Racadot, Sylvie Chabaud, Anthony Montella, Thomas Bachelot, Bertrand Favier, Pascal Pommier, D. Girodet, X. Montbarbon, Jérôme Fayette |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Paclitaxel medicine.medical_treatment Population Cetuximab Antibodies Monoclonal Humanized Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Pharmacology (medical) education Aged Retrospective Studies Aged 80 and over Pharmacology Cisplatin Chemotherapy education.field_of_study business.industry Antibodies Monoclonal Middle Aged medicine.disease Antineoplastic Agents Phytogenic Survival Analysis Head and neck squamous-cell carcinoma Treatment Outcome chemistry Head and Neck Neoplasms Carcinoma Squamous Cell Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 21:553-558 |
| ISSN: | 0959-4973 |
| Popis: | The standard first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma is cisplatin-based chemotherapy, but taxanes can also be beneficial after progression or in patients not eligible for cisplatin. The objective of this retrospective study was to evaluate paclitaxel in this population. We reviewed 66 patients who were treated with paclitaxel at a single institution (Lyon, France) between January 2003 and November 2008. Paclitaxel was administered as first, second or more line of treatment; alone or in combination with carboplatin or cetuximab; every 3 weeks (175 mg/m(2)) or weekly (80 mg/m(2)). Forty-six (70%) patients received paclitaxel as first-line therapy after relapse and 26 (39%) patients as monotherapy. The objective response rate was 30% [95% confidence interval (CI): 20-43%]; 37% (95% CI: 23-52%) in the first line after relapse, and 20% (95% CI: 4-48%) in the second line. Rates were 19% (95% CI: 7-39%) after monotherapy and 36% (95% CI: 20-55%) after combination with carboplatin. Two of the six patients receiving cetuximab had a partial response. The overall survival of all patients was 7.2 months (95% CI: 5.2-8.8). Paclitaxel can be used in symptomatic patients. Although no improvement of overall survival can be expected, paclitaxel treatment is safe and achieves interesting response rates. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|